News

Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease

September 19, 2018

REDWOOD CITY, Calif. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical ...

Read More

Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology

September 17, 2018

REDWOOD CITY, Calif. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical ...

Read More

Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients

September 06, 2018

Amendment Lowers Minimum Age Inclusion Criteria to Four Years, from Eight Years, to Better Reflect ...

Read More
Soleno – Home